HUTCHMED (China) Ltd
HCM15.180USD
+0.610+4.19%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
13.24BCap. mercado
28.07P/E TTM
Más Datos de HUTCHMED (China) Ltd Compañía
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Información de HUTCHMED (China) Ltd
Símbolo de cotizaciónHCM
Nombre de la empresaHUTCHMED (China) Ltd
Fecha de salida a bolsaMay 19, 2006
Director ejecutivoCheng (Chig Fung)
Número de empleados1811
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 19
Dirección48th Floor, Cheung Kong Center, 2 Queen's Road Central
Ciudad
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísHong Kong
Código postal- -
Teléfono85221281188
Sitio Webhttps://www.hutch-med.com/
Símbolo de cotizaciónHCM
Fecha de salida a bolsaMay 19, 2006
Director ejecutivoCheng (Chig Fung)
Ejecutivos de HUTCHMED (China) Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tak Wai (Alvin) Wong
Mr. Tak Wai (Alvin) Wong
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Shao Weng (Daniel) Tan
Prof. Shao Weng (Daniel) Tan
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tak Wai (Alvin) Wong
Mr. Tak Wai (Alvin) Wong
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Shao Weng (Daniel) Tan
Prof. Shao Weng (Daniel) Tan
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2024
FY2023
FY2022
FY2021
FY2020
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
Otro
97.71%
Accionistas
Accionistas
Proporción
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
Otro
97.71%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
2.30%
Investment Advisor
0.65%
Research Firm
0.22%
Hedge Fund
0.13%
Bank and Trust
0.03%
Sovereign Wealth Fund
0.01%
Otro
96.66%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
143
5.89M
3.38%
-5.77M
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Schroder Investment Management (Singapore) Ltd.
1.69M
0.97%
-84.85K
-4.78%
Sep 30, 2025
Allianz Global Investors Asia Pacific Limited
863.00K
0.49%
-15.73K
-1.79%
Sep 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
778.26K
0.45%
-27.37K
-3.40%
Sep 30, 2025
Jane Street Capital, L.L.C.
340.34K
0.2%
+164.38K
+93.42%
Sep 30, 2025
State Street Investment Management (US)
317.50K
0.18%
-11.29K
-3.43%
Sep 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Sep 30, 2025
Amundi Asset Management, SAS
223.33K
0.13%
+65.90K
+41.86%
Sep 30, 2025
M&G Investment Management Ltd.
204.43K
0.12%
-55.19K
-21.26%
Sep 30, 2025
Renaissance Technologies LLC
131.00K
0.08%
+2.00K
+1.55%
Sep 30, 2025
Saint Olive Gestion
100.00K
0.06%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
Proporción0.78%
National Security Emerging Markets Index ETF
Proporción0.35%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
ProShares Ultra Nasdaq Biotechnology
Proporción0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
Proporción0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
Proporción0%
ActivePassive International Equity ETF
Proporción0%
SPDR Portfolio Developed World ex-US ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
